These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2248280)

  • 21. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
    Hofland LJ; van Koetsveld PM; Waaijers M; Zuyderwijk J; Breeman WA; Lamberts SW
    Endocrinology; 1995 Sep; 136(9):3698-706. PubMed ID: 7649075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
    Enzler T; Fojo T
    Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic use of somatostatin analogues in endocrinology].
    Faglia G; Arosio M
    Recenti Prog Med; 1992 Nov; 83(11):626-33. PubMed ID: 1363150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
    Degen L; Beglinger C
    Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin and octreotide in gastroenterology.
    Burroughs AK; McCormick PA
    Aliment Pharmacol Ther; 1991 Aug; 5(4):331-41. PubMed ID: 1685674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.
    Yau H; Kinaan M; Quinn SL; Moraitis AG
    Biologics; 2017; 11():115-122. PubMed ID: 29255345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks.
    Borna RM; Jahr JS; Kmiecik S; Mancuso KF; Kaye AD
    Anesthesiol Clin; 2017 Jun; 35(2):327-339. PubMed ID: 28526153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors.
    Katznelson L; Oppenheim DS; Coughlin JF; Kliman B; Schoenfeld DA; Klibanski A
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1318-25. PubMed ID: 1358910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
    Oberg K
    Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Octreotide, a long-acting somatostatin analog, in the management of postoperative dumping syndrome. An update.
    Lamers CB; Bijlstra AM; Harris AG
    Dig Dis Sci; 1993 Feb; 38(2):359-64. PubMed ID: 8425449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Octreotide treatment of carcinoid hypertensive crisis.
    Warner RR; Mani S; Profeta J; Grunstein E
    Mt Sinai J Med; 1994 Sep; 61(4):349-55. PubMed ID: 7969229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
    Cho KJ; Vinik AI
    Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
    Arnold R; Simon B; Wied M
    Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
    McKeage K; Cheer S; Wagstaff AJ
    Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
    Ben Yosef R; Glaser B; Catane R
    Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.